ESTRO 2025 - Abstract Book

S127

Invited Speaker

ESTRO 2025

Abstract:

Small cell lung cancers (SCLC) are aggressive diseases that require a multidisciplinary approach. Thoracic radiotherapy plays a central role in limited-stage disease, while its role in metastatic stages remains more controversial. With technological advancements, new radiotherapy modalities are being developed to both modulate thoracic dose delivery and improve the precision of brain irradiation. PD-L1 immunotherapy has recently been introduced as consolidation therapy in limited stages and in combination with chemotherapy for metastatic stages. As treatment standards continue to evolve, new strategies are being explored to better optimize treatment indications and/or the combination of radiotherapy with systemic therapies. This lecture aims to describe the current role of radiotherapy in the immunotherapy era and the potential developments in the near future.

4860

Speaker Abstracts New developments in image guidance Jenny Bertholet Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland Abstract The teaching lecture will provide an overview of the main techniques used for image guidance in radiotherapy and the recent developments in this field. The lecture will focus on the most central in-room imaging modalities, including x-ray, MRI and surface guided radiotherapy (SGRT). For each of these, the lecture will cover their use in patient setup, motion management, and potential for adaptive radiotherapy. The presentation will mainly be relevant for photon therapy, but will give some examples on differences and similarities of the use of these techniques also in proton therapy. Perspective on emerging image guidance methods will be briefly discussed

4861

Speaker Abstracts Stepwise overview by the medical physicist Coen Hurkmans Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands

Abstract: In this teaching lecture I will give an overview of the current possibilities of deep learning based segmentation for organs at risk. I will also present an overview of the ways DL segmentation can be evaluated/commissioned before clinical use based on current scientific literature. I will provide information on which improvements in quality, time gain and consistency are possible and what we can expect for future developments for DL OAR segmentation and segmentation in general.

4862

Speaker Abstracts Tailor-made for the RTT? Melissa Verdonk - van den Heuvel